Global Respiratory Drugs Market to 2023 - A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers

Published: September 2017
No. of Pages: 155
Single User License: US $ 4995
Corporate User License: US $ 14985


Respiratory disorders, which affect components of the respiratory system such as the lungs and airway, are a broad range of chronic diseases with a variety of underlying causes, ranging from inherited mutations to pathological inflammation. The respiratory disorders market is dominated by long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) therapies for chronic obstructive pulmonary disease (COPD) and asthma. These drugs stimulate the muscles surrounding the bronchial tubes to relax and open the airways.

Recently approved products in COPD include multiple LABA/LAMA fixed-dose combinations, some of which are forecast to generate over $1 billion by 2023, and include GlaxoSmithKline (GSK)’s triple-combination therapy (fluticasone furoate plus umeclidinium bromide plus vilanterol trifenatate). The approval of novel biologics in the asthma market, including interleukin (IL)-targeting Nucala (mepolizumab), marketed by GSK, is also forecast to have a strong commercial impact on the market. Notable drivers of growth in the cystic fibrosis (CF) market are the recently approved disease-modifying therapies Kalydeco (ivacaftor) and Orkambi (lumacaftor/ivacaftor), both from Vertex.

Respiratory therapy area consists of indications that affect the lungs, bronchi, trachea, larynx, pharynx and nose in different ways, such as the scarring of lung tissue or the excessive production of mucus. Respiratory disease most commonly results in breathing difficulties, which can lead to disruptions in sleep, wheezing, anxiety and stress. In more severe cases shortness of breath (dyspnea) can limit physical activity, affecting both the quality of life and life expectancy of sufferers. The cause of respiratory disorders varies significantly across each indication and includes factors such as environment, occupation, genetic predisposition and aging.

In 2016, GSK was the leading company in terms of revenue generated from respiratory disorder products, accounting for 30.3% of the market, while Vertex had a small market share of 5.3%. However, the emergence of cystic fibrosis transmembrane conductance regulator (CFTR) modulating therapies, which are considered disease-modifying therapies for CF, an indication which has traditionally only had symptomatic treatments, is set to have a substantial clinical and commercial impact. There are only two of these products on the market, Orkambi and Kalydeco, both of which were developed by Vertex.

The report “Global Respiratory Drugs Market to 2023 A Changing Therapeutic Landscape as Key Patents Expire and Biologics, Targeted Therapies and CFTR Modulators for Asthma and Cystic Fibrosis Treatment Emerge as Market Growth Drivers” provides the following analysis -

  • Provides introduction to respiratory disorders, including disease epidemiology, symptoms, pathophysiology, co-morbidities and complications and prognosis. Methods of diagnosis are also provided. The chapter concludes with an analysis of the general treatment options.
  • Provides overview of the marketed products landscape, including product profiles of key marketed products and revenue projections for each of these drugs.
  • Analyzes the respiratory disorders pipeline, detailing, among other parameters, drug distribution by stage of development, molecule type and molecular target, plus an analysis of the key indications in the pipeline: leukemia, lymphoma and myeloma. The clinical trial landscape is also examined, with an emphasis on trends in clinical trial failure rates, duration and size.
  • Presents forecast projections to 2023 on a global level, with forecasts provided for the US, plus aggregate revenue forecasts of the top five EU markets (the UK, France, Germany, Italy and Spain) and Japan. Additionally, revenue forecasts for the major product categories and key players are provided.
  • Assesses the company landscape, with an analysis of the key players, the types of company involved in this therapy area, and whether this therapy area comprises a large proportion of each company’s pipeline portfolio and total revenues.
  • Analyzes trends in co-development and licensing deals, relating to respiratory disorder products. Some of the most prominent deals are discussed in detail.


  • Global revenue from the respiratory market is forecast to increase from $30.9 billion in 2016 to $41.3 billion in 2023, at a compound annual growth rate of 4.23%. What is driving this growth?
  • The leading companies in terms of market share are GSK, AstraZeneca and Boehringer Ingelheim. Which of these are forecast to experience the largest growth?
  • There have been many new approvals in the therapy area. Which drugs will achieve blockbuster status?
  • The market has been dominated by ICS/LABA therapies. What classes of drugs dominate the market and which will dominate over the forecast period?
  • There are 930 respiratory products in the pipeline. What molecular targets are most abundant in the pipeline and what role will pipeline product approvals play in market growth?
  • Respiratory disorders clinical trials have an overall attrition rate of around 70%, what can companies do to maximize their chance of success?

Reasons to buy

  • Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
  • Analyze the respiratory pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at respiratory product clinical trials to provide an insight into the risk associated with attempting to bring pipeline products to market.
  • Predict growth in market size, with in-depth market forecasting from 2016 to 2023. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.
  • Identify commercial opportunities in the respiratory deals landscape by analyzing trends in licensing and co-development deals.

Published By: GBI Research
Product Code: GBI Research1634

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:


  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest: